Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FE 202217
- Development stage
- Unknown
- Lead developer
- Ferring Pharmaceuticals
- Modality
- Peptides
- Administration
- Oral, Intravenous
01
Overview
FE 202217 is an investigational, potent, selective, and short-acting peptidic vasopressin V2 receptor (V2R) agonist developed by Ferring Pharmaceuticals for the treatment of nocturia and nocturnal polyuria. Designed as a synthetic, C-terminally truncated analogue of desmopressin ([Val⁴]dDAVP), FE 202217 features a shorter half-life and a clearance mechanism less dependent on passive glomerular filtration. This design aims to provide a safer therapeutic profile with a reduced risk of prolonged antidiuresis and subsequent hyponatremia, particularly in elderly patients. The compound has been evaluated in a first-in-human Phase 1 single ascending dose (SAD) and crossover study assessing safety, tolerability, pharmacokinetics, and pharmacodynamics via both oral and intravenous routes.
- Other names
- c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-Agm
02
Targets
AVPR2 (Arginine vasopressin V2 receptor)
Beyond the preview
Go deeper on FE 202217.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FE 202217.